MN-DIGI-INTERNATIONAL
14.3.2023 08:01:47 CET | Business Wire | Press release
Digi International®, (NASDAQ: DGII), a leading provider of Internet of Things (IoT) connectivity solutions, today expanded its Digi XBee® 3 Global Cellular family of solutions with the unveiling of Digi XBee® 3 Cellular LTE Cat 1 and Digi XBee® 3 Cellular LTE-M/NB-IoT smart modems for global deployment. These new modules deliver the power and flexibility of the renowned Digi XBee ecosystem — pre-certified for global cellular deployments to accelerate development times and eliminate the costs associated with carrier certification processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005045/en/
Digi XBee® 3 Cellular LTE Cat 1 and Digi XBee® 3 Cellular LTE-M/NB-IoT smart modems for global deployment unveiled at Embedded World 2023. (Graphic: Business Wire)
The newest additions to the Digi XBee Global Cellular family are dependable, compact solutions with BLE and end-device carrier certifications that can be used worldwide and are equipped with Global Navigation Satellite System (GNSS) positioning. They deliver simplified and future-proof solutions for developers and original equipment manufacturers (OEMs) looking to add reliable cellular IoT connectivity to their devices or IoT gateways. With pre-integrated certifications, the XBee 3 Global family supports LTE Cat 1, LTE-M and NB-IoT networks, with 2G/3G fallback — for applications that require reliable cellular connectivity, anywhere in the world. These solutions support low-power applications such as meters, smart sensors and other fixed assets that send small portions of data.
Digi XBee Global Cellular family smart modems are designed to be provisioned, managed and monitored by Digi Remote Manager® (Digi RM). Additionally, they support MicroPython programming, Bluetooth, GNSS positioning for geolocation and Digi TrustFence® security.
“Our Digi XBee 3 Global Cellular family expands the XBee ecosystem of RF modules, gateways, adapters and software — giving OEMs access to the smallest, pre-certified modems for cellular networks that will save thousands in development time and money,” said Steve Ericson, Vice President and General Manager of Digi’s OEM Solutions division. “Pre-certification, along with the integration of advanced software and security, and a full ecosystem of tools supports rapid time-to-market.”
Digi XBee 3 Global Cellular Cat 1
Designed for applications that require higher throughput, the XBee 3 Cat 1 smart modem gives customers a single SKU for deployment of cellular products anywhere in the world. It includes 2G/3G fallback for use in regions and countries where Cat 1 isn’t available.
Digi XBee 3 Global Cellular LTE-M/NB-IoT
Offering low-power cellular connectivity, Digi XBee 3 LTE-M/NB-IoT modules are designed for applications that require data collection from edge devices — supporting higher data rates, lower latency and cell tower handoff, making it ideal for mobile applications and asset tracking.
Delivering the lowest power consumption and data transfer rates available, NB-IoT is ideal for battery-powered and passive devices, which transmit small amounts of data at intermittent times.
All smart modems within the XBee Cellular family solution include MicroPython programming resources to enable direct custom scripting, 2G/3G fallback to ensure connectivity, GNSS for accurate location services, OTA firmware updates and access to Digi Remote Manager for over-the-air software updates and monitoring. With built-in Digi TrustFence® security, identity and data privacy features, customers can tap into more than 175 controls to protect against new and evolving cyber threats. The Digi XBee Mobile App and Digi XBee Studio® tool suite simplify setup, configuration and testing. Digi XBee Data Plans are also available for a wide variety of cellular connectivity requirements.
Digi XBee 3 Global Cellular Family solutions are available now. For more information, visit: https://www.digi.com/products/embedded-systems/digi-xbee/cellular-modems.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005045/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom